# A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

> **NCT06382311** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 991 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Flu Pandemic mRNA_Dose level 1
- **BIOLOGICAL:** Flu Pandemic mRNA_Dose level 2
- **BIOLOGICAL:** Flu Pandemic mRNA_ Dose level 3.
- **BIOLOGICAL:** Flu Pandemic mRNA_ Dose level 4
- **BIOLOGICAL:** Flu Pandemic mRNA_Dose level 5
- **BIOLOGICAL:** Flu Pandemic mRNA_Dose level 6
- **BIOLOGICAL:** Influenza virus vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06382311
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-18
- **Primary completion:** 2026-01-13
- **Final completion:** 2026-01-13
- **Target enrollment:** 991 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06382311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06382311, "A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06382311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*